Skip to content

Honasa Skin Renew Peptide Under Eye Cream for dark circle and ageing.

A single blind clinical study to evaluate the activity of Honasa Skin Renew Peptide Under Eye Cream for dark circle and ageing. - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106616
Enrollment
36
Registered
2026-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Skin Renew Peptide Under Eye Cream: Test Product: Skin Renew peptide Under eye Cream Dose: : Gently apply the cream around eye area, Route of Administration: Topical, Dura

Sponsors

Honasa Consumer Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender Male and Female aged between 25-45. 2. Non-pregnant, non-lactating female 3. Subject with crow feet and dark circle. 4. Subject willing to give written informed consent 5. Women of child bearing potential must have a negative urine pregnancy test. 6. Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE. 7. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation, natural or artificial for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2. Volunteers with skin conditions such as eczema, psoriasis, etc 3. Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 4. Have open sore or open lesions in the treatment area 5. Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 6. Have participated in any interventional clinical trial in the previous 30 days. 7. Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 8. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids. 9. Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Design outcomes

Primary

MeasureTime frame
1. Change in Skin Hydration (Corneometer) 2. Change in TEWL (Tewameter) 3. Change in Skin Melanin (Mexameter) 4. Change in Wrinkles (Visioface) 5. Change in Skin Firmness/Elasticity (Cutometer)Timepoint: Day 0, 24 hour(Hydration), Day 14

Secondary

MeasureTime frame
1. Dermatological Evaluations 2. HD Imaging with DSLR 3. SGATimepoint: Day0, Day14

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026